Minor
Suspected
Description
Azithromycin is a weak CYP3A4 inhibitor that can modestly raise loratadine plasma levels; the clinical impact is minimal given loratadine's wide therapeutic index and low cardiac risk.
Mécanisme
Azithromycin inhibits CYP3A4 to a minor degree, reducing hepatic metabolism of loratadine; azithromycin itself carries a small QT-prolonging potential, creating a theoretical additive cardiac risk.
Signification clinique
No significant QT changes or adverse events are expected at standard doses in patients without underlying cardiac risk factors.
Prise en charge
No dose adjustment required; exercise caution in patients with QT prolongation risk factors or electrolyte abnormalities.